

Literatur

1. **Barrick B, Campbell EJ, Owen C:** Leukocyte proteases in wound healing: roles in physiologic and pathologic processes. *Wound Rep Reg* 1999; 7: 410–422.
2. **Grinnell F, Ho CH, Wysocki A:** Degradation of fibronectin and vitronectin in chronic wound fluid: analysis by cell blotting, immunoblotting, cell adhesion assays. *J Invest Dermatol* 1992; 98: 410–416.
3. **Grinnell F, Zhu M:** Fibronectin degradation in chronic wounds depends on the relative levels of elastase, a1-proteinase inhibitor, and a2-macroglobulin. *J Invest Dermatol* 1996; 106: 335–341.
4. **Jünger M, Steins A, Hahn M, Hafner HM:** Microcirculatory dysfunction in chronic venous insufficiency. *Microcirculation* 2000; 7: S3–S12.
5. **Lauer G, Sollberg S, Cole M, Flamme J, Mann K, Krieg T, Eming SA:** Expression and Proteolysis of VEGF is increased in chronic wounds. *J Invest Dermatol* 2000; 115: 12–18.
6. **Lauer G, Sollberg S, Cole M, Krieg T, Eming SA:** Generation of a novel proteolytic resistant VEGF165 variant by a site directed mutation at the plasmin sensitive cleavage site. *FEBS Letters* 2002; 531: 309–313.
7. **Nissen NN, Polverini PJ, Koch AE, Volin MV, Gamelli RL, DiPietro LA:** VEGF mediates angiogenic activity during the proliferative phase of wound healing. *Am J Pathol* 1998; 152: 1445–1452.
8. **Parks WC:** Matrix metalloproteinases in repair. *Wound Rep Reg* 1999; 7: 423–432.
9. **Pechen M, Lahayer T, Henning B, Weyl A, Simon JC, Vanscheidt W:** Expression of the adhesion molecules ICAM-1, VCAM-1, LFA-1 and VLA-4 in the skin is modulated in progressing stages of chronic venous insufficiency. *Acta Derm Venereol* 1999; 79: 27–32.
10. **Rosner K, Ross C, Karlsmark T, Petersen AA, Gottrup F, Lange Vejlsgaard G:** Immunohistochemical characterization of the cutaneous cellular infiltrate in different areas of chronic leg ulcers. *APMIS* 1995; 103: 293–299.
11. **Takase S, Schmid-Schönbein G, Bergan JJ:** Leukocyte activation in patients with venous insufficiency. *J Vasc Surg* 1999; 30: 148–156.
12. **Whiston RJ, Hallett MB, Davies EV, Harding KG, Lane IF:** Inappropriate neutrophil activation in venous disease. *Br J Surg* 1994; 81: 695–698.
13. **Wlaschek M, Peus D, Achterberg V, Meyer-Ingold W, Scharffetter-Kochanek K:** Protease inhibitors protect growth factor activity in chronic wounds. *Br J Dermatol* 1997; 137: 646–663.
14. **Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J:** Vascular-specific growth factors and blood vessel formation. *Nature* 2000; 407: 242–248.

Dr. Sabine Eming, Universität Köln, Joseph-Stelzmann-Str. 9, 50931 Köln